A pooled analysis of data from four trials of Novo Nordisk’s obesity drug semaglutide found treatment reduced the risk of cardiovascular death or worsening heart failure by 31% compared to placebo.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,